InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: Oren1976 post# 855

Sunday, 04/23/2017 4:30:51 PM

Sunday, April 23, 2017 4:30:51 PM

Post# of 2099
Patient selection criteria is key, imo. Dror has stated that they did not hand select ph2 patients to improve results because that would set the drug up for failure in ph3. It was his response to questions regarding why some ph3 rgbm trials were failing.

ph2 and ph3 are similar in that they did compare avastin alone and avastin+vb111.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News